🇺🇸 FDA

Intelligence · Clinical Pipeline

AbbVie Deutschland GmbH Pipeline

All ClinicalTrials.gov programs at AbbVie Deutschland GmbH — phase, modality, and trial IDs.

Programs
102

Quick answer

AbbVie Deutschland GmbH has 102 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Alphagan 2 mg/ml colirio en solución, Brimonidine Tartrate 0.2% w/v Eye Drops., Mirvetuximab Soravtansine, Pred Forte 10 mg/ml colirio en suspensión, Pred Forte 1% w/v, Eye Drops Suspension

    AbbVie Deutschland GmbH & Co. KG

    Recurrent Ovarian Cancer with High Folate Receptor-Alpha Expression

    phase 2 small molecule active

    1 trial

  2. BEVACIZUMAB, IRINOTECAN, FOLINIC ACID, Telisotuzumab adizutecan, FLUOROURACIL

    AbbVie Deutschland GmbH & Co. KG

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  3. Budigalimab, Placebo for Budigalimab (ABBV-181) - 0.9% Sodium Chloride or DILUENT, ABBV-382, Placebo for ABBV-382 Solution for Infusion

    AbbVie Deutschland GmbH & Co. KG

    HIV infection

    phase 2 small molecule active

    1 trial

  4. Budigalimab, Sorafenib STADA 200 mg Filmtabletten, Livmoniplimab, Kisplyx 4 mg hard capsules

    AbbVie Deutschland GmbH & Co. KG

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  5. Budigalimab, Telisotuzumab adizutecan, Cisplatin 1mg/ml Injection BP, Carboplatin 10 mg/ml Intravenous Infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion

    AbbVie Deutschland GmbH & Co. KG

    Advanced or Metastatic Non-Squamous NSCLC

    phase 2 small molecule active

    1 trial

  6. CARBOPLATIN, ETOPOSIDE, CARBOPLATIN, ATEZOLIZUMAB, ABBV-706

    AbbVie Deutschland GmbH & Co. KG

    Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  7. CARBOPLATIN, Mirvetuximab Soravtansine, BEVACIZUMAB

    AbbVie Deutschland GmbH & Co. KG

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  8. DARATUMUMAB, DEXAMETHASONE, POMALIDOMIDE, DEXAMETHASONE, POMALIDOMIDE, POMALIDOMIDE, Surzetoclax, Surzetoclax, DEXAMETHASONE

    AbbVie Deutschland GmbH & Co. KG

    Multiple Myeloma (MM).

    phase 2 small molecule active

    1 trial

  9. DARZALEX 20 mg/mL concentrate for solution for infusion, DARZALEX 1800 mg solution for injection, DARZALEX 20 mg/mL concentrate for solution for infusion, VELCADE 3.5 mg powder for solution for injection, DARZALEX 20 mg/mL concentrate for solution for infusion, Venetoclax, DEXAMETHASONE

    AbbVie Deutschland GmbH & Co. KG

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  10. FOLINIC ACID, FLUOROURACIL, BEVACIZUMAB, Telisotuzumab adizutecan, FOLINIC ACID, PANITUMUMAB, OXALIPLATIN

    AbbVie Deutschland GmbH & Co. KG

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  11. Fluorouracil 50mg/ml Injection., FOLINIC ACID, Eftozanermin alfa, Telisotuzumab adizutecan, Oxaliplatin 5 mg/ml concentrate for solution for infusion

    AbbVie Deutschland GmbH & Co. KG

    Adenocarcinoma of the gastroesophageal junction

    phase 2 small molecule active

    1 trial

  12. Humira 40 mg solution for injection in pre-filled syringe, Lutikizumab, Humira 80 mg solution for injection in pre-filled syringe, Humira 40 mg solution for injection in pre-filled syringe, Lutikizumab, Humira 40 mg solution for injection in pre-filled syringe, Humira 40 mg solution for injection in pre-filled syringe

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  13. Iberdomide, Iberdomide, Etentamig, Iberdomide, Iberdomide

    AbbVie Deutschland GmbH & Co. KG

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  14. Ibrutinib, IMBRUVICA 140 mg film-coated tablets, Ibrutinib, Prednison acis 5 mg, Tabletten, Prednison acis 20 mg, Tabletten, Ibrutinib, Prednison acis 50 mg, Tabletten

    AbbVie Deutschland GmbH & Co. KG

    Chronic Graft Versus Host Disease (cGVHD)

    phase 2 small molecule active

    1 trial

  15. LENALIDOMIDE, LENALIDOMIDE, DEXAMETHASONE, CARFILZOMIB, LENALIDOMIDE, DARATUMUMAB, LENALIDOMIDE, Etentamig, LENALIDOMIDE, LENALIDOMIDE, DEXAMETHASONE

    AbbVie Deutschland GmbH & Co. KG

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  16. Lutikizumab, USP/Ph. Eur.ABBV-323, Universal Placebo (Lutikizumab, Ravagalimab)

    AbbVie Deutschland GmbH & Co. KG

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  17. MEDI0618, Placebo to match MEDI0618

    AbbVie Deutschland GmbH & Co. KG

    Migraine

    phase 2 small molecule active

    1 trial

  18. Navitoclax, Navitoclax, RUXOLITINIB

    AbbVie Deutschland GmbH & Co. KG

    Myelofibrosis

    phase 2 small molecule active

    1 trial

  19. PIVEKIMAB SUNIRINE

    AbbVie Deutschland GmbH & Co. KG

    Acute Myeloid Leukemia and other blood cancers

    phase 2 small molecule active

    1 trial

  20. Placebo for ABBV-142

    AbbVie Deutschland GmbH & Co. KG

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule active

    1 trial

  21. Polivy 30 mg powder for concentrate for solution for infusion., Epcoritamab (GEN3013), Truxima 100 mg concentrate for solution for infusion, IMBRUVICA 140 mg hard capsules, Golcadomide, Revlimid 10 mg hard capsules, IMBRUVICA 140 mg hard capsules, PIRTOBRUTINIB, Cyclophosphamide Injection 500 mg., Venetoclax, Venetoclax, Epcoritamab (GEN3013), Revlimid 25 mg hard capsules, Venetoclax, Decortin® H 20 mg Tabletten, Truxima 500 mg concentrate for solution for infusion, Decortin® H 5 mg Tabletten, Adriblastin®

    AbbVie Deutschland GmbH & Co. KG

    B-cell Non-Hodgkin's lymphoma, diffuse large B-cell lymphoma

    phase 2 small molecule active

    1 trial

  22. Pred Forte 10 mg/ml colirio en suspensión, Pred Forte 1% w/v, Eye Drops Suspension, Brimonidine Tartrate 0.2% w/v Eye Drops., Alphagan 2 mg/ml colirio en solución, IMGN151

    AbbVie Deutschland GmbH & Co. KG

    Recurrent endometrial cancer, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer (EOC), recurrent cervical cancer

    phase 2 small molecule active

    1 trial

  23. Study evaluating the Safety and Efficacy of Etentamig (ABBV-383) in Subjects with Light Chain Amyloidosis

    AbbVie Deutschland GmbH & Co. KG

    Light Chain Amyloidosis

    phase 2 other active

    1 trial

  24. Surabgene Lomparvovec (ABBV-RGX-314), Surabgene Lomparvovec (ABBV-RGX-314)

    AbbVie Deutschland GmbH & Co. KG

    Neovascular age-related macular degeneration

    phase 2 small molecule active

    1 trial

  25. TAXOTERE 20 mg/1 ml concentrate for solution for infusion, Budigalimab, Livmoniplimab, Paclitaxel 6 mg/mL concentrate for solution for infusion, Gemcitabine 38 mg/mL concentrate for solution for infusion

    AbbVie Deutschland GmbH & Co. KG

    Urothelial Carcinoma, Metastatic Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  26. Telisotuzumab Vedotin

    AbbVie Deutschland GmbH & Co. KG

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  27. Telisotuzumab adizutecan

    AbbVie Deutschland GmbH & Co. KG

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  28. Telisotuzumab adizutecan

    AbbVie Deutschland GmbH & Co. KG

    Locally Advanced or Metastatic Solid Tumours that harbour MET Amplification gene

    phase 2 small molecule active

    1 trial

  29. Upadacitinib, Upadacitinib

    AbbVie Deutschland GmbH & Co. KG

    Crohn's Disease (CD)

    phase 2 small molecule active

    1 trial

  30. Vidaza 25 mg/ml powder for suspension for injection, Venclyxto 100 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, PIVEKIMAB SUNIRINE, Venclyxto 100 mg film-coated tablets

    AbbVie Deutschland GmbH & Co. KG

    CD123 positive Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  31. A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications

    AbbVie Deutschland GmbH & Co. KG

    locally advanced or metastatic solid tumors

    phase 1 other active

    1 trial

  32. A Phase 1 first in human study evaluating safety, pharmacokinetics and efficacy of ABBV-400 as monotherapy and in combination with bevacizumab in adult subjects with advanced solid tumors

    AbbVie Deutschland GmbH & Co. KG

    Advanced solid tumors including (but not limited to), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), gastric/gastroesophageal junction adenocarcinoma (GEA), colorectal cancer (CRC), and renal cell carcinoma (RCC)

    phase 1 other active

    1 trial

  33. A Phase 1 first-in-human study evaluating safety, pharmacokinetics and efficacy of ABBV-706 as monotherapy and in combination with budigalimab (ABBV-181), carboplatin, or cisplatin in adult subjects with advanced solid tumors.

    AbbVie Deutschland GmbH & Co. KG

    Advanced solid tumors

    phase 1 other active

    1 trial

  34. A Phase 1b, Open-Label Study of Eftozanermin Alfa (ABBV-621) in Combination with Bortezomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

    AbbVie Deutschland GmbH & Co. KG

    Multiple Myeloma

    phase 1 other active

    1 trial

  35. A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

    AbbVie Deutschland GmbH & Co. KG

    Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia

    phase 1 other active

    1 trial

  36. A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

    AbbVie Deutschland GmbH & Co. KG

    Myelodysplastic Syndromes (MDS)

    phase 1 other active

    1 trial

  37. A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Compared to Oral Lenvatinib Capsules in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

    AbbVie Deutschland GmbH & Co. KG

    Squamous-Cell Non-Small Cell Lung Cancer, Hepatocellular Cancer

    phase 1 other active

    1 trial

  38. A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

    AbbVie Deutschland GmbH & Co. KG

    Relapsed/Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  39. A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants with Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)

    AbbVie Deutschland GmbH & Co. KG

    Systemic Lupus Erythematosus, Sjogren's disease

    phase 1 other active

    1 trial

  40. A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

    AbbVie Deutschland GmbH & Co. KG

    Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer

    phase 1 other active

    1 trial

  41. A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

    AbbVie Deutschland GmbH & Co. KG

    Follicular lymphoma (FL), Chronic lymphocytic leukemia (CLL), Diffuse large b-cell lymphoma (DLBCL), B-cell malignancies

    phase 1 other active

    1 trial

  42. A Study with ABBV-155 Alone and in Combination with Taxane Therapy in Adults with Relapsed and/or Refractory Solid Tumors

    AbbVie Deutschland GmbH & Co. KG

    Patients with relapsed or refractory solid tumors, including: Small cell lung cancer (SCLC); Non-small cell cancer (NSCLC); Breast cancer

    phase 1 other active

    1 trial

  43. A study to characterize the safety, efficacy, pharmacokinetics of subcutaneous administration of Etentamig (ABBV-383) in patients with relapsed or refractory Multiple Myeloma

    AbbVie Deutschland GmbH & Co. KG

    Relapsed or Refractory Multiple Myeloma (R/R MM)

    phase 1 other active

    1 trial

  44. Jakavi 10 mg tablets, CELECOXIB , Navitoclax, Navitoclax, Jakavi 10 mg tablets, Jakavi 5 mg tablets, Jakavi 5 mg tablets, Jakavi 5 mg tablets, Jakavi 10 mg tablets

    AbbVie Deutschland GmbH & Co. KG

    Myelofibrosis, Myeloproliferative Neoplasms

    phase 1 small molecule active

    1 trial

  45. Livmoniplimab, Budigalimab

    AbbVie Deutschland GmbH & Co. KG

    Locally Advanced or Metastatic Solid Tumors, Solid Tumors

    phase 1 small molecule active

    1 trial

  46. Mass Balance Study of [14C] ABBV-932 in Healthy Male Volunteers

    AbbVie Deutschland GmbH & Co. KG

    Healthy Volunteers

    phase 1 other active

    1 trial

  47. PIVEKIMAB SUNIRINE

    AbbVie Deutschland GmbH & Co. KG

    Relapsed or Refractory Acute Myeloid Leukemia; Acute Myeloid Leukemia, Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  48. Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

    AbbVie Deutschland GmbH & Co. KG

    Non-Hodgkin's Lymphoma

    phase 1 other active

    1 trial

Frequently asked questions

How many pipeline programs does AbbVie Deutschland GmbH have?

102 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.